mardi 4 juin 2019

Onco Actu du 4 juin 2019


4.12 BIOPSIES LIQUIDES



Johns Hopkins Spinout to Bring CancerSEEK Test to Clinic [Genome Web]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



Is it Time to Integrate Polygenic Risk Scores into Clinical Practice? Let’s Do the Science First and Follow the Evidence Wherever it Takes Us! [Genomics and Precision health]










5. TRAITEMENTS



Novel protocol significantly improves outcomes in locally advanced pancreatic [Mass. General Hospital]











5.2.3 PHARMA - ÉCONOMIE



Inhibrx, Fresh Off $40M Funding to Advance Cancer Drugs, Eyes IPO [Xconomy]











5.3 TRAITEMENTS - FDA, EMA, NICE...



The FDA’s accelerated drug approval program is failing to protect cancer patients [Science-Based Medicine]










FDA to make it easier for doctors to get unapproved cancer drugs for patients [Washington Post]











FDA announces Project Facilitate to assist physicians seeking access to unapproved therapies for patients with cancer [FDA]










US aims to help more cancer patients try experimental drugs [AP]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



FDA approves addition of survival data to gilteritinib label for refractory AML with a FLT3 mutation [FDA]











6.10.1 POLITIQUES (USA)



‘Right-to-try’ laws provide little access to investigational drugs. We created a process that does [STAT]











6.12 ETHIQUE



Research integrity is much more than misconduct [Nature]










6.6 PUBLICATIONS



Plan S Is Still Coming [In The Pipeline]











Plan S and the Transformation of Scholarly Communication: Are We Missing the Woods? [The Scholarly Kitchen]











6.7.2 APPLIS



Tempus Announces (TIME) Trial Service, a New Integrated Molecular Evaluation that Leverages Artificial Intelligence to Rapidly Match Cancer Patients to Clinical Trials [Tempus]











6.9 CONTROVERSES



Jury smacks J&J with $325M talc verdict after a series of other wins [Fierce Pharma]